Looking for Fingerprints: Bioanalytical Characterization of Biosimilars - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Looking for Fingerprints: Bioanalytical Characterization of Biosimilars
Extensive physicochemical characterization of the innovator product and the proposed biosimilar provides the foundation for demonstrating biosimilarity.


Pharmaceutical Technology
Volume 36, Issue 6, pp. 36-41

More difficult than it appears

Although copying an innovator's product may appear easier than developing a novel therapeutic, the difficulties of engineering one product to match an existing product cannot be underestimated. Rudd points out that it is considerably more difficult to produce a biosimilar product than simply inserting a DNA construct into a cell line and expecting that the innovator product will be faithfully reproduced. For biologics, the process is intimately connected with the disposition of the final product, but the biosimilar manufacturer does not have knowledge of the processes used by the innovator.

Xu points out, however, that manufacturers have better understanding of and more control over processes than they did 20 years ago. Implementation of process analytical technology and use of quality-by-design principles in setting up the process will greatly facilitate production of a consistent product. For any biosimilar, he recommends engaging the analytical team early in the process so that the developer can determine how process changes will affect critical quality attributes. In some instances, there may be correlations between process parameters and protein structural attributes, allowing the protein attributes to be fine-tuned.

EMA is well ahead of the US in biosimilars development, having approved its first biosimilar in 2006, and with 14 biosimilar products now on the market. EMA has already released guidance documents that are specific for different product types, including epoetins, filgastrims, and a draft guidance for monoclonal antibodies (8–10). Such product-specific specifications will doubtless be released by FDA in time, and will help better define what a fingerprint looks like.

References

1. FDA, Draft Guidance, Scientific Considerations in Demonstrating Bioimilarity to a Reference Product (Rockville, MD, February 2012).

2. FDA, Draft Guidance, Quality Considerations in Demonstrating Bioimilarity to a Reference Product (Rockville, MD, February 2012).

3. FDA, Guidance for Industry on Biosimilars: Q & As Regarding Implementation of the BPCI Act of 2009 (Rockville, MD, February 2012).

4. FDA, Generic Enoxaparin Questions and Answers, http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm220037.htm, accessed May 2012.

5. ICH, Q6B Specifications: Test Procedures and Acceptance Criteria for. Biotechnological/Biological Products (1999).

6. P. Hossler, SF Khattak, and ZJ Li, Glycobiol. 19 (9), 936–949 (2009).

7. D. Fernandes, BioPharm Intl. 24 (1) (2011).

8. EMA, Guidance on Similar Medicinal Products Containing Recombinant Erythropoietins (Sept. 2010).

9 . EMA, Guidance on Biosimilar Medicinal Products Containing Recombinant Granulocyte-Colony Stimulating Factor (June 2006).

10. EMA, Draft Guideline, Similar Biological Medicinal Products Containing Monoclonal Antibodies (Sept. 2010).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
20%
Attracting a skilled workforce
28%
Obtaining/maintaining adequate financing
12%
Regulatory compliance
40%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here